Table 1 Baseline demographics and clinical characteristics (n = 510)
Value, n (%) | |
|---|---|
Gender | |
Male | 376 (73.7) |
Female | 134 (26.3) |
Age, years | |
6 to 12 years | 366 (71.8) |
13 to 17 years | 144 (28.2) |
Mean ± SD | 10.4 ± 3.1 |
Median (min to max) | 10.0 (6 to 17) |
Treatment Category | |
Hospitalization | 22 (4.3) |
Outpatient | 488 (95.7) |
Duration of ASD, years | |
< 1 year | 216 (42.4) |
≥ 1 to < 2 years | 46 (9.0) |
≥ 2 to < 3 years | 25 (4.9) |
≥ 3 years | 86 (16.9) |
Unknown | 137 (26.9) |
Mean ± SD (n = 373) | 1.70 ± 2.51 |
Median (min to max) | 0.50 (0 to 15.3) |
Intellectual disability | |
None | 387 (75.9) |
Total | 123 (24.1) |
Mild | 68 (13.3) |
Moderate | 30 (5.9) |
Severe | 19 (3.7) |
Most severe | 6 (1.2) |
Comorbidities | |
None | 144 (28.2) |
Total | 366 (71.8) |
ADHDa | 271 (53.1) |
LDa | 57 (11.2) |
Tic disordersa | 35 (6.9) |
Sleep disordersa | 90 (17.6) |
Concomitants for ASD | |
None | 461 (90.4) |
Total | 49 (9.6) |
Risperidonea | 26 (5.1) |
Antidepressantsa | 36 (7.1) |
ADHD drugsa | 6 (1.2) |
Concomitants for other condition | |
None | 257 (50.4) |
Total | 253 (49.6) |
Methylphenidate hydrochlorideab | 86 (16.9) |
Guanfacine hydrochlorideab | 43 (8.4) |
Atomoxetine hydrochlorideab | 42 (8.2) |
Risperidoneab | 30 (5.9) |
Ramelteonab | 17 (3.3) |
Sodium valproateab | 12 (2.4) |
Yokukansanab | 12 (2.4) |
CGI-S | |
1: Normal | 1 (0.2) |
2: Minimally ill | 1 (0.2) |
3: Mildly ill | 42 (8.2) |
4: Moderately ill | 282 (55.3) |
5: Makedly ill | 150 (29.4) |
6: Severely ill | 30 (5.9) |
7: Very severely ill | 4 (0.8) |
Mean ± SD | 4.3 ± 0.8 |
Median (min to max) | 4.0 (1 to 7) |